QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)

This study has been completed.
Celgene Corporation
Information provided by:
PETHEMA Foundation
ClinicalTrials.gov Identifier:
First received: May 28, 2007
Last updated: July 30, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2013
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
No publications provided by PETHEMA Foundation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):